4-AMINOBUTANAL


Molecule Category	Free-form
UNII	VTX8N8R7G2
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	DZQLQEYLEYWJIB-UHFFFAOYSA-N
Smiles	NCCCC=O
InChI	InChI=1S/C4H9NO/c5-3-1-2-4-6/h4H,1-3,5H2

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C4H9NO
Molecular Weight	87.12
AlogP	-0.58
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	3.0
Polar Surface Area	43.09
Molecular species	BASE
Aromatic Rings	0.0
Heavy Atoms	6.0

Assay Description	Organism	Bioactivity
Antiparasitic activity against promastigotes of Leishmania infantum MHOM-TN-80-IPT1 assessed as decrease in parasite vitality at 1 to 5 mM measured at 4th day by microscopic analysis	Leishmania infantum	None
Increase in vitality of Leishmania infantum MHOM-TN-80-IPT1 promastigotes at 1 to 5 mM measured at 7th day by microscopic analysis	Leishmania infantum	None
Increase in density of Leishmania infantum MHOM-TN-80-IPT1 promastigotes at 1 to 5 mM measured at 7th day by microscopic analysis	Leishmania infantum	None
Antiparasitic activity against promastigotes of Leishmania infantum MHOM-TN-80-IPT1 assessed as decrease in parasite density at 1 to 5 mM measured at 4th day by microscopic analysis	Leishmania infantum	None

Cross References

Resources	Reference
ChEMBL	CHEMBL2261442
FDA SRS	VTX8N8R7G2
PubChem	118
SureChEMBL	SCHEMBL60217

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).